India Ratings and Research has reaffirmed Torrent Pharmaceuticals' credit rating at IND AA with a stable outlook, also assigning an A1 rating to its commercial paper program. The company, a leading player in the Indian pharmaceutical market with a global presence, reported a 30.46% rise in net profit and a 14.66% increase in net sales for Q2 September 2025 compared to the previous year. Torrent Pharma's securities committee will meet to consider issuing secured non-convertible debentures.